Hilma Biocare – Trenbolone Mix 150mg/ml




Trenbolone mix 150 is an oil based solution of trenbolone acetate, trenbolone enanthate and
trenbolone hexahydroben- zylcarbonate for IM injection. Trenbolone is an anabolic steroid
with significant anabolic and androgenic effects. The fast acting ester produces a rapid
increase in serum trenbolone levels while the slow ester provides a continued elevation
thereafter for a duration of 7 – 10 days. Trenbolone promotes significant increases in
strength, muscle anabolism, appetite, and aggression and has been demonstrated to reduce
body fat.


Males: Trenbolone use may be indicated in patients where substantial weight gain and
increases in musculature are required for patient health after substantial losses of body
mass especially in instances where caloric intake is limited and other anabolic therapies
have previously failed. The physician and patient must consider the risks of therapy versus
the potential benefits.


Anabolic steroids are synthetic derivatives of testosterone. Certain clinical effects and
adverse reactions demonstrate the androgenic properties of these drugs. Complete
dissociation of anabolic and androgenic effects has not been achieved. The actions of
anabolic steroids are thus similar to those of male sex hormones. Anabolic steroids suppress
the gonadotropic functions of the pituitary and may exert a direct effect upon the testes.
During exogenous administration of anabolic androgens, endogenous testosterone release
is inhibited through inhibition of pituitary luteinizing hormone (LH). At large doses,
spermatogenesis may be suppressed through feedback follicle-stimulating hormone (FSH).
inhibition of pituitary Trenbolone binds strongly to the androgen receptor and its action is
generally considered to derive therefrom. It produces significant anabolism even during
periods of limited caloric restriction. The literature offers conflicting reports of the
susceptibility of trenbolone to aromatize into estrogen or reduce to a dihydrotestosterone
derivative. Rat studies have suggested that trenbolone may exert effects typically associated
with dihydrotestosterone through a non-DHT pathway potentially with direct receptor action.
It has been suggested that trenbolone may reduce cortisol production through an
indeterminate pathway of activity upon glucocorticoid receptors. Trenbolone has been
demonstrated to promote muscle growth, appetite, aggression, and the production of red
blood cells through the production of erythropoietic stimulating factors. Trenbolone is
suspected of selective binding of the progesterone receptor potentially acting as both an
agonist and an antagonist. It has been suggested that trenbolone is capable of binding to the
prolactin receptor. Thus serum progesterone and serum prolactin levels should be monitored
during treatment and if elevated anti-progesterone and anti-prolactin agents should be


Male: Gynecomastia, excessive frequency and duration of penile erections, oligospermia.

Skin and Appendages: Hirsutism, male pattern baldness and acne, gynecomastia.

Fluid/electrolyte Disturbances: Retention of sodium, chloride, water, potassium, calcium, and
inorganic phosphates.

Gastrointestinal: Nausea, cholestatic jaundice, alterations in liver function tests;
hepatocellular neoplasms, peliosis hepatitis, hepatic adenomas, nephritis, and cholestatic

Hematologic: Suppression of clotting factors II, V, VII, & X; bleeding in patients on anticoagulant therapy. Neurological: Increased libido, headache, anxiety, depression, extreme
agitation, irritability, and generalized paresthesia. Trenbolone may cause severe aggressive

Other: Serum lipid changes, hypertension, hypercalcaemia, hypertension, oedema, priapism,
and potentiation of sleep apnea.


Patients on oral anticoagulant therapy require close monitoring especially when androgens
are started or stopped.

Diabetics: androgens may alter the metabolism of oral hypoglycemic agents or may change
insulin sensitivity in patients with diabetes mellitus which may require adjustment of dosage
of insulin and other hypoglycemic drugs. May alter metabolism of cyclosporine. Avoid other
hepatotoxic medications.


Patients with known hypersensitivity to any ingredients in this product. Patients with known
or suspected carcinomas of the breast, testis, or prostate. Patients with severe heart
disease, liver disease, or kidney disease or with a history of epilepsy. Products containing
androgens should not be used in women as they may cause virilization and fetal harm.


Women, children and elderly males should not use. Trenbolone should be used with extreme
caution and with the lowest dosage and duration of treatment necessary for clinical response
pursuant to the advice of a qualified physician. Because androgens may alter serum
cholesterol concentration, caution should be used when administering these drugs to
patients with a history of myocardial infarction or coronary artery disease, Trenbolone may
increase aggressiveness and cause psychiatric changes. At the first sign of psychiatric
changes discon- tinue use of trenbolone and contact a physician. Due to its hepatotoxicity,
liver functions should be monitored. Discontinue on signs of jaundicing.
PATIENT MONITORING Serum Cholesterol, HDL, LDL, TG. Hemoglobin and Hematocrit,
Hepatic function tests – AST/ALT, Prostatic specific antigen – PSA, Testosterone: total, free,
and bioavailable. Dihydrotestosterone & Estradiol. Progesterone, Prolactin, Blood Pressure.
Male patients over 40 should undergo a digital rectal examination and evaluate PSA prior to
androgen use. Periodic evaluations of the prostate should continue while on androgen
therapy, especially in patients with difficulty in urination or with changes in voiding habits.


Adult male: 50 – 150mg every 3-5 days for duration limited to 4 weeks under care of a


Trenbolone mix 150 mg/ml, 10 ml multiple dose vial.


Store in a cool dry place between 15 – 25°C. Protect from light.

Laboratory Test



There are no reviews yet.

Be the first to review “Hilma Biocare – Trenbolone Mix 150mg/ml”

Your email address will not be published.